No Detail Found!

Clinical and biochemical outcomes of Sodium-Glucose CoTransporter-2 (SGLT2) Inhibitors in Type-2 Diabetes Mellitus Patients as a fourth oral anti diabetic medicine

Author(s)
Muhammad Saleem Section of Endocrinology and Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan.
Sajjad Ali Khan Section of Endocrinology and Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan.
Zafar Aleem Suchal Section of Endocrinology and Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan.
Nanik Ram Section of Endocrinology and Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan.
Abstract
Objectives: To evaluate the clinical and biochemical effects of (SGLT2) inhibitors as a fourth oral antidiabetic drug in patients with Type-2 diabetes mellitus (T2DM). Methods: In a tertiary hospital in Karachi, Pakistan, a retrospective assessment of patient medical records was conducted from January 1, 2017 to December 31, 2020.A total of one hundred patients (mean age [Standard Deviation]: 53.8 [9.63] years) with poorly controlled T2DM were included. Data was collected before the SGLT-2 inhibitor was added, as well as three and six months after the medicine was started. Weight, BMI, blood pressure (BP), HbA1c, SGPT, and Creatinine were measured at the start and during the study. Results: There was a significant reduction in HbA1c (p-value < 0.001) with a mean reduction (MR) of 0.81+1.02% at three months and 1.07+1.11% at six months. A mean weight reduction (p-value < 0.001) of 1.83+2.32 kg at three months and 4.02+6.04 kg at 6 months, respectively, was recorded. A mean BMI reduction of 0.69+0.95 kgm-2 at three months and 2.13+3.41 kgm-2 at six months of follow up, respectively were recorded. A systolic blood pressure (SBP) also showed a significant reduction (p-value < 0.05) with a MR of 5.9+15.76 mmHg at three months and 6.37+18.33 mmHg at 6 months, respectively. Non-significant variation in creatinine and SGPT was also noted. Conclusions: SGLT-2 is an effective oral anti-diabetic medicine that can help individuals with diabetes who are currently using glucose-lowering oral anti-diabetic medications. These medications can help diabetic patients stick to their regimen.
Publication Details
Page(s) 1255-1259
DOI DOI not available
Published Journal: Pakistan Journal of Medical Sciences, Volume: 38, Issue: 5, Year: 2022

Request the full text from PASTIC

Keywords
Weight loss, T2DM, SGLT2 Inhibitors
0

Citations

0

Downloads

124

Views